SAM
STRO icon

Simplify Asset Management’s Sutro Biopharma STRO Stock Holding History

Simplify Asset Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,000
Closed -$678K – 124
2024
Q1 		$678K Hold
12,000
– – 0.04% 80
2023
Q4 		$515K Hold
12,000
– – 0.05% 91
2023
Q3 		$416K Hold
12,000
– – 0.05% 102
2023
Q2 		$558K Hold
12,000
– – 0.07% 90
2023
Q1 		$554K Buy
+12,000
New +$762K 0.08% 82

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Simplify Asset Management's STRO Position: Q2 2024 in Review

Simplify Asset Management sold out of Sutro Biopharma (STRO) in Q2 2024, closing a stake of 12,000 shares — an estimated $678K sold.

Simplify Asset Management first reported a position in STRO in Q1 2023 and held it in 5 quarters. The position peaked at $678K in Q1 2024. 119 funds tracked by Wall St. Rank hold STRO as of Q2 2024.

  • Simplify Asset Management reported no remaining Sutro Biopharma position as of Q2 2024 after selling out during the quarter.
  • Simplify Asset Management sold 12,000 Sutro Biopharma shares in Q2 2024, an estimated $678K.
  • Simplify Asset Management first reported a position in Sutro Biopharma in Q1 2023 and held it in 5 quarters.
  • Simplify Asset Management's Sutro Biopharma position peaked at $678K in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2024.

Based on Simplify Asset Management's 13F filing for Q2 2024, filed 12 Aug 2024.